Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

Abstract

Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of drugs that inhibit B cell receptor activation, FC-γ receptor signaling, and osteoclast proliferation. Following on approval for treatment of hematologic malignancies, BTK inhibitors are now under investigation to treat a number of different autoimmune diseases, including rheumatoid arthritis (RA). While the results of BTK inhibitors in RA animal models have been promising, the ensuing human clinical trial outcomes have been rather equivocal. This review will outline the mechanisms of BTK inhibition and its potential impact on immune mediated disease, the types of BTK inhibitors being studied for RA, the findings from both preclinical and clinical trials of BTK inhibitors in RA, and directions for future research.

Keywords:

• evobrutinib
• spebrutinib
• acalabrutinib
• fenebrutinib
• rheumatoid arthritis
• Bruton’s tyrosine kinase

Disclosure

Dr Eric M Ruderman reports on personal fees from Genentech, outside of the submitted work. The authors report no other conflicts of interest in this work.